Neuland Laboratories Ltd Q2 FY26 – From Bulk Drugs to Big Dreams, The API Alchemist Hits ₹514 Cr Sales & 195% PAT Surge!
1. At a Glance
Welcome to the quarterly episode of Neuland Laboratories: The API Magician Chronicles. In Q2 FY26, the Hyderabad-based bulk drug specialist has gone full “Breaking Bad meets Wall Street,” mixing complex chemistry with profit potions. Sales shot up to ₹514 crore (up a juicy 65.4% YoY), while net profit tripled to ₹96.8 crore (195% YoY).
The stock now trades at a mind-bending ₹17,837 per share with a market cap of ₹22,885 crore—enough to make small pharma rivals consider selling their microscopes. But with a P/E ratio of 117, this is not your typical value play—it’s a story stock where every DMF feels like a scene from Money Heist.
Operating profit margin clocked a strong 21.4%, ROCE a healthy 18.7%, and ROE 14.8%. Even as the company’s promoter holding dipped to 32.6%, the FIIs are queuing up like shoppers during Big Billion Days.
So, what’s happening at Neuland? Are they just selling APIs—or quietly building an empire that could make big pharma sweat? Let’s find out.
2. Introduction – The API Factory That Turned Into a Chemistry Cult
Neuland Laboratories is not your neighborhood bulk drug supplier anymore. What started as a humble API manufacturer for domestic pharma companies has evolved into a globally respected supplier to innovators across the US, Europe, and Japan.
In a world where APIs (Active Pharmaceutical Ingredients) are the backbone of every pill you pop, Neuland is the pharmacist’s pharmacist. But unlike the boring generic manufacturers, Neuland plays in the tough, high-margin league—where you make fewer molecules but earn more per gram.
And boy, have they done it well. With 973+ DMFs filed, 204+ patents, and 67 active US DMFs, Neuland has quietly become one of India’s sharpest API exporters. The company’s pivot from commodity APIs to complex, patented, and custom manufacturing (CMS) has been nothing short of a chemistry miracle.
Still, the valuation looks more like a designer drug overdose—P/E of 117, EV/EBITDA of 66.2. Either the Street thinks Neuland is the next Divi’s Laboratories, or it’s pricing in a Nobel Prize in organic synthesis.
What do you think—scientific genius or valuation madness?
3. Business Model – WTF Do They Even Do?
In the simplest terms: Neuland cooks up molecules for the global pharma industry. But like any Indian recipe, the real flavor lies in the proportions.
1. Prime APIs (24% of FY24 revenue): This is the “everyday dosa batter” of Neuland—about 15 high-volume APIs like Levetiracetam (used in epilepsy) and Mirtazapine (for depression). Low margins, high volumes, and fierce competition. The segment still keeps the plants running and the cash flow stable.
2. Specialty APIs (22%): This is the gourmet kitchen—25+ complex, niche APIs with limited competition. Some even have patent protection. Top five molecules account for 70% of this segment’s revenue. It’s the zone where Neuland flexes its chemistry muscles.
3. Custom Manufacturing Solutions (CMS) – 49%: The company’s “chef’s table.” Here, Neuland works with global innovators on developing, scaling, and manufacturing APIs that are still under patent. They currently manage 88 active projects—16 in pre-clinical, 54 in development, and 18 commercial. Each project could potentially turn into a long-term money-spinner, as clients stick around for years once the molecule succeeds.
4. Others (5%): Small miscellaneous stuff—likely internal R&D supply and contract revenue.
In short, Neuland has turned its manufacturing sites into chemistry theme parks—where Prime pays the bills, Specialty wins the hearts, and CMS builds the future.
4. Financials Overview
Quarterly Results (₹ in Crores)
Metric
Q2 FY26
Q2 FY25
Q1 FY26
YoY %
QoQ %
Revenue
514
311
293
65.4%
75.4%
EBITDA
156
62
34
151.6%
358.8%
PAT
96.8
33
14
193.6%
591%
EPS (₹)
75.5
25.6
10.8
195%
599%
If this quarter were a cricket match, Neuland just hit back-to-back sixes on every delivery. Revenue grew 65%, profits tripled, and margins came roaring back to 30%.
Annualised EPS (₹75.5 × 4 = ₹302). At ₹17,837, that’s a forward P/E of ~59x—still high, but hey, this is chemistry, not grocery.
5. Valuation Discussion – Fair Value Range (Educational Only)
Let’s run the numbers like a cautious chemist:
a) P/E Method Assuming a sustainable EPS range between ₹187 (TTM) and ₹302 (annualised Q2):
At 40x (industry avg) → ₹7,480 – ₹12,080
At 60x (premium CMS rerating) → ₹11,220 – ₹18,120
b) EV/EBITDA Method TTM EBITDA = ₹328 crore; EV/EBITDA of peers (Divi’s, Suven, Laurus) ≈ 25–35x.
Fair EV range = ₹8,200 – ₹11,500 crore → Fair price range ₹6,400 – ₹9,000
c) DCF Snapshot (very conservative) Assume 15% CAGR earnings for 5 years, discount 10%, terminal 4% → Value per share ₹9,500 – ₹11,500.
✅ Fair Value Range: ₹9,000 – ₹12,000 (Educational Estimate Only)
Disclaimer: This range is for educational purposes, not investment advice. Please consult your calculator, your cat, or your conscience before acting.
6. What’s Cooking – News, Triggers, Drama
Neuland’s Q2 FY26 press release was spicy enough to trend on Pharma Twitter:
Total income ₹516.1 crore, EBITDA ₹156.9 crore, PAT ₹96.5 crore.
Land acquisition worth ₹17.2 crore in Telangana for new capacity.
Capex plan: ₹342 crore approved for expansion.
US FDA inspection: Unit 2 passed with a single minor observation—basically an A+ in compliance.
Leadership twist: Effective April 2026, Saharsh Rao becomes CEO & MD, while Sucheth Rao moves to Executive Vice Chairman. The Rao brothers are clearly turning succession planning into a family science experiment.
